Answers are grounded in this paper and cite their sources.
Blocking the chaperones: Heat shock protein 90 (Hsp90) has emerged as a promising target for the treatment of cancer, Alzheimer's and Parkinson's diseases, motor impairments, multiple sclerosis, and other disorders. Progress toward the development of both N- and C-terminal inhibitors is described.
No takes yet. Share an insight, caveat, or question.
Chaudhury et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: